Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
July 01, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
June 29, 2021 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed...
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021
June 22, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
May 25, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock
April 15, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 17, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
March 10, 2021 00:20 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization...
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
March 08, 2021 17:01 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization...
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments
March 08, 2021 16:05 ET
|
Avid Bioservices, Inc
-- Third Quarter Revenue Increased 61% to $21.8 Million -- -- Signed $74 Million in New Orders to End the Quarter with a Backlog of $120 Million -- -- First Phase of Myford Expansion on Target,...
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
March 03, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...